Oral GPR40/FFAR1 agonists: which compounds could be relevant to thymic aging?
Following the recent GW9508 thymus paper, I looked into orally active compounds targeting GPR40, also called FFAR1.
The study reported increased thymus size and improvements in thymic epithelial cells and T-cell populations in aged mice. The proposed mechanism involves increased intracellular calcium, AMPK activation and suppression of excessive ERK1/2 signaling. However, GW9508 was administered by intraperitoneal injection; the study did not establish oral efficacy or lasting rejuvenation after treatment stopped. Original paper. (onlinelibrary.wiley.com)
Below is a broad overview of the main named oral candidates I could identify, rather than an exhaustive inventory of patented compounds.
How to read the scores
These are subjective evidence ratings, not validated clinical scores or head-to-head potency comparisons.
- Activity/benefit evidence: 1 = cellular evidence; 2 = animal efficacy; 3 = early human pharmacodynamic or efficacy evidence; 4 = convincing phase II efficacy; 5 = efficacy supported by phase III studies. Most human benefits studied concern glucose metabolism.
- Safety: higher means more reassuring evidence. 1 = major demonstrated concern; 2 = limited human experience and/or unresolved signals; 3 = reasonably reassuring short-term clinical data; 4–5 would require substantially stronger long-term evidence.
- NR = not reliably rateable. Missing safety data should not be mistaken for either safety or toxicity.
Neither score measures proven anti-aging efficacy.
| Compound |
Activity / benefit evidence |
Safety |
What the evidence actually shows |
| GW9508 |
2/5 |
NR |
The compound used in the thymus study. A separate rat pharmacokinetic study found approximately 55% oral bioavailability, making oral delivery plausible—but oral thymic efficacy and human safety remain unestablished. (pubmed.ncbi.nlm.nih.gov, onlinelibrary.wiley.com) |
| HD6277 |
4/5 |
3/5 |
A 12-week randomized phase II trial in 112 people with type 2 diabetes reported placebo-adjusted HbA1c reductions of approximately 0.73–0.85 percentage points, with reassuring short-term tolerability. No thymus outcomes were studied. (pubmed.ncbi.nlm.nih.gov) |
| SCO-267 |
3/5 |
2/5 |
An oral full agonist, with human evidence of increased insulin and gut-hormone secretion and improved glucose tolerance. Gastrointestinal adverse effects occurred; repeated-dose exposure in the published phase I study was brief. (pmc.ncbi.nlm.nih.gov) |
| CPL207280 |
2/5 |
2/5 |
Animal metabolic efficacy and published oral phase I human pharmacokinetic/tolerability data. The first-in-human study does not establish clinically meaningful glucose-lowering efficacy; longer-term safety remains uncertain. (sciencedirect.com, dom-pubs.onlinelibrary.wiley.com) |
| MK-8666 |
3/5 |
2/5 |
Improved glucose control in a small, 14-day human study. One participant developed elevated liver enzymes, limiting how reassuring the short-term safety findings can be considered. (pmc.ncbi.nlm.nih.gov) |
| LY2922470 |
3/5 |
NR |
Early clinical work reported glucose-lowering proof of concept following repeated oral dosing. The available evidence is insufficient for a confident long-term safety rating. (pubs.acs.org) |
| K-757 |
3/5 |
2/5 |
A gut-targeted GPR40 agonist studied alone and with K-833, a GPR119 agonist. In a phase IIa obesity study, weight loss with K-757 alone did not reach statistical significance; the combination did. Gastrointestinal adverse events were more common with active treatment. Combination results cannot be attributed to K-757 alone. (dom-pubs.onlinelibrary.wiley.com) |
| Fasiglifam / TAK-875 |
5/5 |
1/5 |
Strong human glucose-lowering evidence, including phase III trials, but development was terminated because of drug-induced liver injury. Its high activity score is emphatically not a favorable overall assessment. (clinicaltrialsregister.eu, pubmed.ncbi.nlm.nih.gov) |
There are also several orally active preclinical research compounds:
| Compound |
Activity / benefit evidence |
Human safety |
Main evidence |
| AM-1638 |
2/5 |
NR |
Orally bioavailable full agonist with metabolic efficacy in rodents. (pmc.ncbi.nlm.nih.gov) |
| AM-5262 |
2/5 |
NR |
Full agonist with oral rodent activity and strong incretin responses. (pmc.ncbi.nlm.nih.gov) |
| TUG-770 |
2/5 |
NR |
Improved glucose tolerance in mice, with activity maintained during 29 days of daily oral treatment. (pmc.ncbi.nlm.nih.gov) |
| MK-2305 |
2/5 |
NR |
Oral preclinical GPR40 agonist studied in metabolic experiments. (pmc.ncbi.nlm.nih.gov) |
| DS-1558 |
2/5 |
NR |
Orally bioavailable agonist with glucose-lowering activity in diabetic rats. (pmc.ncbi.nlm.nih.gov) |
| CNX-011-67 |
2/5 |
NR |
Oral animal studies reported improved insulin secretion and delayed progression of hyperglycemia. (link.springer.com) |
Other historical oral development candidates include AMG 837, JTT-851, P11187, LY2881835 and LY2922083. Public clinical results are uneven, so I would leave their comparative benefit and safety scores NR, rather than infer success from the fact that they entered trials. (amgentrials.com, clinicaltrials.gov, piramal.com, pubs.acs.org)
Which seem most relevant to follow scientifically?
My research shortlist would be GW9508, because it has the direct thymus evidence; HD6277, because of its published phase II human results; and SCO-267, because its full-agonist pharmacology has been demonstrated in humans.
However, activating the same receptor does not guarantee reproducing the thymus result. GPR40 agonists can differ in signaling: for example, AM-1638 and AM-5262 recruit both Gq and Gs pathways, whereas several other agonists predominantly recruit Gq. Tissue exposure also matters—particularly for a gut-targeted compound such as K-757. Greater insulin or GLP-1 secretion does not establish greater thymic benefit. (pmc.ncbi.nlm.nih.gov, cdn.clinicaltrials.gov)
The most informative next experiment would compare orally administered candidates in aged animals, measuring thymic drug exposure, epithelial-cell recovery, new T-cell production, immune function and persistence after withdrawal.
Has anyone seen these newer agonists tested in thymic epithelial cells, or any oral replication of the GW9508 thymus findings?